Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 16/20 | 0.80 |
| ▸ | CNR2 | P34972 | 15/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16173737 | 1.00 | CNR1 (0.80) | CNR1CNR2 | |
| SCHEMBL16173798 | 0.97 | CNR2 (0.78) | CNR1CNR2 | |
| SCHEMBL16173740 | 0.91 | CNR2 (0.68) | CNR1CNR2 | |
| SCHEMBL16173791 | 0.89 | CNR2 (1.00) | CNR1CNR2 | |
| SCHEMBL30497883 | 0.89 | CNR2 (1.00) | CNR1CNR2 | |
| SCHEMBL16173763 | 0.87 | CNR2 (0.66) | CNR1CNR2 | |
| SCHEMBL16173775 | 0.87 | CNR2 (0.66) | CNR1CNR2 | |
| SCHEMBL16173765 | 0.84 | CNR2 (0.60) | CNR1CNR2 | |
| SCHEMBL16173729 | 0.83 | CNR2 (0.59) | CNR1CNR2 | |
| SCHEMBL16173738 | 0.82 | CNR2 (0.86) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-3664795-B1 | CANNABIS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN AND INFLAMMATION RELATED WITH DENTAL PULP AND BONE REGENERATION RELATED TO DENTAL JAW BONE DEFECTS | CANNIBITE BVBA (BE) | 2024-06-19 | — | — | EP | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| CN-117805259-A | Method for rapidly analyzing 87 synthetic cannabinoids and metabolites thereof in urine after enzymolysis | 司法鉴定科学研究院 | 2024-04-02 | — | — | CN | claimed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-3664795-B1 | CANNABIS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN AND INFLAMMATION RELATED WITH DENTAL PULP AND BONE REGENERATION RELATED TO DENTAL JAW BONE DEFECTS | CANNIBITE BVBA (BE) | 2024-06-19 | — | — | EP | disclosed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| CN-117805259-A | Method for rapidly analyzing 87 synthetic cannabinoids and metabolites thereof in urine after enzymolysis | 司法鉴定科学研究院 | 2024-04-02 | — | — | CN | disclosed |
| WO-2024020572-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PTSD | NEW YORK STEM CELL FOUNDATION, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20230270763-A1 | METHOD OF TREATING CORONOVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | PASCAL BIOSCIENCES INC (CA) | 2023-08-31 | — | — | US | disclosed |
| US-11612581-B2 | Cannabis and derivatives thereof for the treatment of pain and inflammation related with dental pulp and bone regeneration related to dental jaw bone defects | CANNIBITE BVBA | 2023-03-28 | — | — | US | disclosed |
| CN-111627902-B | Programmable overvoltage protection device with SGT and thyristor | 电子科技大学 | 2022-06-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | CNR1 221/4885CNR2 204/4885 |
| US-20230270763-A1 | METHOD OF TREATING CORONOVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | CNR1, CNR2, SARS1 | CNR1 1/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.